Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.40 -9.09%
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Nike (NKE) Tops Q4 EPS by 8c
- Trump's annual disclosures show $236 million in crypto proceeds, gifts worth $370,000
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
